CRISPR THERAPEUTICS AG Research and Development Expense
CRISPR THERAPEUTICS AG (CRSP) reported Research and Development Expense of $67.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-03
- CRISPR THERAPEUTICS AG research and development expense for the quarter ending 2026-06-30 was $67.15M, a 3.92% decline year-over-year.
- CRISPR THERAPEUTICS AG research and development expense for the quarter ending 2026-03-31 was $68.57M, a 5.39% decline year-over-year.
- CRISPR THERAPEUTICS AG research and development expense for the quarter ending 2025-12-31 was $83.53M, a 16.43% increase year-over-year.
- CRISPR THERAPEUTICS AG research and development expense for the quarter ending 2025-09-30 was $58.90M, a 28.31% decline year-over-year.
- CRISPR THERAPEUTICS AG research and development expense for fiscal 2025 was $284.81M, a 8.20% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG research and development expense for fiscal 2024 was $310.24M, a 19.90% decline from fiscal 2023.
- CRISPR THERAPEUTICS AG research and development expense for fiscal 2023 was $387.33M, a 16.10% decline from fiscal 2022.
- CRISPR THERAPEUTICS AG research and development expense for fiscal 2022 was $461.64M, a 35.55% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $67.15M 10-Q · filed 2026-08-03 | $135.73M 10-Q · filed 2026-08-03 | $219.25M derived: sum of 3 quarters · filed 2026-08-03 | $278.15M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2026-03-31 | $68.57M 10-Q · filed 2026-05-04 | $152.10M derived: sum of 2 quarters · filed 2026-05-04 | $211.00M derived: sum of 3 quarters · filed 2026-05-04 | $280.90M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-12-31 | $83.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $142.43M derived: sum of 2 quarters · filed 2026-02-12 | $212.32M derived: sum of 3 quarters · filed 2026-08-03 | $284.81M 10-K · filed 2026-02-12 | ||||
| 2025-09-30 | $58.90M 10-Q · filed 2025-11-10 | $128.80M derived: sum of 2 quarters · filed 2026-08-03 | $201.28M 10-Q · filed 2025-11-10 | $273.02M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-06-30 | $69.89M 10-Q · filed 2026-08-03 | $142.38M 10-Q · filed 2026-08-03 | $214.12M derived: sum of 3 quarters · filed 2026-08-03 | $296.28M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-03-31 | $72.48M 10-Q · filed 2026-05-04 | $144.22M derived: sum of 2 quarters · filed 2026-05-04 | $226.38M derived: sum of 3 quarters · filed 2026-05-04 | $306.55M derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | $71.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $153.90M derived: sum of 2 quarters · filed 2026-02-12 | $234.06M derived: sum of 3 quarters · filed 2026-02-12 | $310.24M 10-K · filed 2026-02-12 | $320.65M 10-K · filed 2025-02-11 | |||
| 2024-09-30 | $82.16M 10-Q · filed 2025-11-10 | $162.32M derived: sum of 2 quarters · filed 2025-11-10 | $238.50M 10-Q · filed 2025-11-10 | $333.64M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-06-30 | $80.17M 10-Q · filed 2025-08-04 | $156.34M 10-Q · filed 2025-08-04 | $251.48M derived: sum of 3 quarters · filed 2026-02-12 | $342.18M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-03-31 | $76.17M 10-Q · filed 2025-05-06 | $171.32M derived: sum of 2 quarters · filed 2026-02-12 | $262.01M derived: sum of 3 quarters · filed 2026-02-12 | $363.57M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2023-12-31 | $95.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $185.84M derived: sum of 2 quarters · filed 2026-02-12 | $287.40M derived: sum of 3 quarters · filed 2026-02-12 | $387.33M 10-K · filed 2026-02-12 | ||||
| 2023-09-30 | $90.70M 10-Q · filed 2024-11-05 | $192.25M derived: sum of 2 quarters · filed 2024-11-05 | $292.19M 10-Q · filed 2024-11-05 | $395.74M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-06-30 | $101.56M 10-Q · filed 2024-08-05 | $201.49M 10-Q · filed 2024-08-05 | $305.05M derived: sum of 3 quarters · filed 2025-02-11 | $421.67M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-03-31 | $99.94M 10-Q · filed 2024-05-08 | $203.49M derived: sum of 2 quarters · filed 2025-02-11 | $320.11M derived: sum of 3 quarters · filed 2025-02-11 | $443.33M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2022-12-31 | $103.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $220.18M derived: sum of 2 quarters · filed 2025-02-11 | $343.40M derived: sum of 3 quarters · filed 2025-02-11 | $461.64M 10-K · filed 2025-02-11 | ||||
| 2022-09-30 | $116.62M 10-Q · filed 2023-11-06 | $239.84M derived: sum of 2 quarters · filed 2023-11-06 | $358.09M 10-Q · filed 2023-11-06 | $461.19M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | $123.22M 10-Q · filed 2023-08-07 | $241.47M 10-Q · filed 2023-08-07 | $344.56M derived: sum of 3 quarters · filed 2024-02-21 | $428.06M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | $118.25M 10-Q · filed 2023-05-08 | $221.34M derived: sum of 2 quarters · filed 2024-02-21 | $304.84M derived: sum of 3 quarters · filed 2024-02-21 | $387.17M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $103.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $186.59M derived: sum of 2 quarters · filed 2024-02-21 | $268.93M derived: sum of 3 quarters · filed 2024-02-21 | $340.57M 10-K · filed 2024-02-21 | $438.63M 10-K · filed 2022-02-15 | |||
| 2021-09-30 | $83.50M 10-Q · filed 2022-11-01 | $105.32M 10-Q · filed 2021-11-03 | $165.83M derived: sum of 2 quarters · filed 2022-11-01 | $237.47M 10-Q · filed 2022-11-01 | $304.16M 10-Q · filed 2021-11-03 | $273.25M derived: sum of 4 quarters · filed 2023-02-21 | ||
| 2021-06-30 | $82.33M 10-Q · filed 2022-08-08 | $108.28M 10-Q · filed 2021-07-29 | $153.97M 10-Q · filed 2022-08-08 | $198.84M 10-Q · filed 2021-07-29 | $189.75M derived: sum of 3 quarters · filed 2023-02-21 | $260.76M derived: sum of 4 quarters · filed 2023-02-21 | ||
| 2021-03-31 | $70.62M 10-Q · filed 2022-05-09 | $90.56M 10-Q · filed 2021-04-27 | $107.42M derived: sum of 2 quarters · filed 2023-02-21 | $178.43M derived: sum of 3 quarters · filed 2023-02-21 | $237.81M derived: sum of 4 quarters · filed 2023-02-21 | |||
| 2020-12-31 | $36.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $107.81M derived: sum of 2 quarters · filed 2023-02-21 | $167.19M derived: sum of 3 quarters · filed 2023-02-21 | $221.38M 10-K · filed 2023-02-21 | $266.95M 10-K · filed 2021-02-16 | |||
| 2020-09-30 | $71.01M 10-Q · filed 2021-11-03 | $130.39M derived: sum of 2 quarters · filed 2021-11-03 | $184.58M 10-Q · filed 2021-11-03 | $233.34M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-06-30 | $59.38M 10-Q · filed 2021-07-29 | $113.57M 10-Q · filed 2021-07-29 | $162.33M derived: sum of 3 quarters · filed 2022-02-15 | $219.58M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-03-31 | $54.19M 10-Q · filed 2021-04-27 | $102.95M derived: sum of 2 quarters · filed 2022-02-15 | $160.20M derived: sum of 3 quarters · filed 2022-02-15 | $199.73M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2019-12-31 | $48.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $106.01M derived: sum of 2 quarters · filed 2022-02-15 | $145.54M derived: sum of 3 quarters · filed 2022-02-15 | $179.36M 10-K · filed 2022-02-15 | ||||
| 2019-09-30 | $57.25M 10-Q · filed 2020-10-28 | $96.78M derived: sum of 2 quarters · filed 2020-10-28 | $130.60M 10-Q · filed 2020-10-28 | $159.40M derived: sum of 4 quarters · filed 2021-02-16 | ||||
| 2019-06-30 | $39.53M 10-Q · filed 2020-07-27 | $73.36M 10-Q · filed 2020-07-27 | $102.16M derived: sum of 3 quarters · filed 2021-02-16 | $141.98M derived: sum of 4 quarters · filed 2021-02-16 | ||||
| 2019-03-31 | $33.82M 10-Q · filed 2020-04-28 | $62.62M derived: sum of 2 quarters · filed 2021-02-16 | $102.44M derived: sum of 3 quarters · filed 2021-02-16 | $128.08M derived: sum of 4 quarters · filed 2021-02-16 | ||||
| 2018-12-31 | $28.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $68.62M derived: sum of 2 quarters · filed 2021-02-16 | $94.25M derived: sum of 3 quarters · filed 2021-02-16 | $113.77M 10-K · filed 2021-02-16 | ||||
| 2018-09-30 | $39.82M 10-Q · filed 2019-10-28 | $65.45M derived: sum of 2 quarters · filed 2019-10-28 | $84.97M 10-Q · filed 2019-10-28 | $105.00M derived: sum of 4 quarters · filed 2020-02-12 | ||||
| 2018-06-30 | $25.63M 10-Q · filed 2019-07-29 | $45.15M 10-Q · filed 2019-07-29 | $65.18M derived: sum of 3 quarters · filed 2020-02-12 | $83.03M derived: sum of 4 quarters · filed 2020-02-12 | ||||
| 2018-03-31 | $19.52M 10-Q · filed 2019-04-29 | $39.55M derived: sum of 2 quarters · filed 2020-02-12 | $57.39M derived: sum of 3 quarters · filed 2020-02-12 | $74.51M derived: sum of 4 quarters · filed 2020-02-12 | ||||
| 2017-12-31 | $20.03M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $37.88M derived: sum of 2 quarters · filed 2020-02-12 | $54.99M derived: sum of 3 quarters · filed 2020-02-12 | $69.80M 10-K · filed 2020-02-12 | ||||
| 2017-09-30 | $17.84M 10-Q · filed 2018-11-07 | $34.97M derived: sum of 2 quarters · filed 2018-11-07 | $49.77M 10-Q · filed 2018-11-07 | $65.34M derived: sum of 4 quarters · filed 2019-02-25 | ||||
| 2017-06-30 | $17.12M 10-Q · filed 2018-08-07 | $31.93M 10-Q · filed 2018-08-07 | $47.50M derived: sum of 3 quarters · filed 2019-02-25 | $59.55M derived: sum of 4 quarters · filed 2019-02-25 | ||||
| 2017-03-31 | $14.80M 10-Q · filed 2018-05-08 | $30.38M derived: sum of 2 quarters · filed 2019-02-25 | $42.43M derived: sum of 3 quarters · filed 2019-02-25 | $51.03M derived: sum of 4 quarters · filed 2019-02-25 | ||||
| 2016-12-31 | $15.57M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $27.62M derived: sum of 2 quarters · filed 2019-02-25 | $36.23M derived: sum of 3 quarters · filed 2019-02-25 | $42.24M 10-K · filed 2019-02-25 | ||||
| 2016-09-30 | $12.05M 10-Q · filed 2017-11-08 | $20.65M derived: sum of 2 quarters · filed 2017-11-08 | $26.67M 10-Q · filed 2017-11-08 | $32.84M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2016-06-30 | $8.60M 10-Q · filed 2017-08-10 | $14.61M 10-Q · filed 2017-08-10 | $20.79M derived: sum of 3 quarters · filed 2018-03-08 | $24.54M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2016-03-31 | $6.01M 10-Q · filed 2017-05-11 | $12.19M derived: sum of 2 quarters · filed 2018-03-08 | $15.94M derived: sum of 3 quarters · filed 2018-03-08 | |||||
| 2015-12-31 | $6.17M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $9.92M derived: sum of 2 quarters · filed 2018-03-08 | $12.57M 10-K · filed 2018-03-08 | |||||
| 2015-09-30 | $3.75M 10-Q · filed 2016-11-22 | $6.40M 10-Q · filed 2016-11-22 | ||||||
| 2014-12-31 | $1.51M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |